Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $63.52M |
| Net Income (Most Recent Fiscal Year) | $-376.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.63 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -661.31% |
| Net Margin (Trailing 12 Months) | -661.31% |
| Return on Equity (Trailing 12 Months) | -43.15% |
| Return on Assets (Trailing 12 Months) | -31.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 101.16M |
| Free Float | 97.62M |
| Market Capitalization | $1.71B |
| Average Volume (Last 20 Days) | 2.47M |
| Beta (Past 60 Months) | 2.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |